RE: RE: RE: RE: Immunocidin Apparently Not Stooge...
I am still a bit confused as to why the NRs, and any other for-distribution correspondence to shareholders or the market, highlights "mammary carcinoma" while the marketing to vets (who actually know what mammary carcinoma is) are handed the terms "dog cancer" and "88% cure rate"?
In all seriousness, I do realize that a penny stock biotech, with a 100 mil spend on the MCC platform,may be leery of mentioning its revolutionary new treatment for dog cancer, considering its commonality with the human disease and its notoriety and negative implications. Why would you want to rain negativity on anyone's Thanksgiving?